GlassScriptPhysician profile
Ashley M Weiland
NPI 1841842697
$1,246.36
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $545 · 2022: $701.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $273.16 | 2021-2022 | |
| Lilly USA, LLC | $208.21 | 2021-2022 | |
| Novo Nordisk INC | $191.98 | 2021-2022 | |
| Abbvie INC. | $146.05 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $76.70 | 2021-2022 | |
| Ibsa Pharma INC. | $66.47 | 2021-2022 | |
| Amarin Pharma, INC. | $51.62 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $43.66 | 2021 | |
| Amgen INC. | $40.06 | 2021-2022 | |
| Pfizer INC. | $39.20 | 2021 | |
| Mylan Specialty L.P. | $30.63 | 2021 | |
| Hologic Sales and Service, LLC | $22.31 | 2021 | |
| Esperion Therapeutics, INC. | $16.85 | 2021 | |
| Sanofi Pasteur INC. | $15.93 | 2021 | |
| Janssen Pharmaceuticals, INC | $11.92 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $11.61 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Weiland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.